Shoulder Innovations (SI) Morgan Stanley 24th Annual Global Healthcare Conference summary

Strategic partnerships and product innovation

• Exclusive partnership with ALM Ortho enables earlier entry into complex cases, with commercial impact expected to grow meaningfully by 2027.

• Recent launches include the N-22 Humeral Head and glenosphere for patients with metal allergies, expanding the addressable patient base.

• InSet Go and InSet Clutch products streamline procedures and are expected to broaden adoption among surgeons, with launches imminent.

• Robotics development (InSet Neo) is ahead of schedule, targeting regulatory clearance in H1 2027, and aims to make robotics accessible to all facility types.

• ProVoyance software is evolving to shift clinical decision-making to preoperative planning, reducing intraoperative risk and supporting future patient-matched implants.

Commercial growth and market penetration

• Core and contender surgeon base stands at 134 out of 1,800 high-volume specialists, indicating significant runway for further penetration.

• Surgeons are increasingly adopting reverse procedures as their entry point, reflecting broader acceptance and innovation in the product suite.

• Surgeon-led education events and symposiums are highly scalable and effective, accelerating surgeon progression through the adoption funnel.

• Growth is primarily driven by share capture from competitors, focusing on high-volume, technology-forward specialists.

Clinical evidence and product differentiation

• Registry data from over 700 patients shows low rates of acromial fracture and subluxation, with promising range of motion and strength outcomes.

• Subscapularis-sparing initiative leverages low-profile implants and aims for easier, less invasive procedures, with adoption expected to grow over years as supporting evidence emerges.